| abstract |
The biological activity of the nucleic acid ligand is controlled (ie promoted or inhibited) to produce the desired biological effect in vivo. This is done by altering the binding of the nucleic acid ligand to the target, or by administering a modulator, ie a regulator, that degrades, otherwise cleaves, metabolizes or destroys the nucleic acid ligand while the ligand effect is still effective. . The modulators of the present invention can be administered in real time as needed based on a variety of factors such as the progression of the patient's condition and the physician's judgment on how to achieve optimal treatment. Thus, the present invention provides a controllable treatment method for the first time in a therapeutic unit of nucleic acid ligand therapy. |